Evidence for approved and investigational oral incretin therapies, dual and triple receptor agonists, amylin-based strategies, established antidiabetic drugs, and adjunctive approaches targeting body composition are summarized.
Karolina Hoffmann, Weronika Pucek, Wiktoria Skrzypek et al.· Journal of Pharmacy & Ph...· 0 citations
Triple-negative breast cancer (TNBC) is a tough, heterogeneous subtype of breast cancer characterised by the absence of oestrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 expression, which results in limited therapeutic options and bad clinical outcomes. Several nanomedicine strategi...
Osteoporosis is a major skeletal disorder. Increasing evidence suggests that gut microbiota-derived mechanisms may contribute to bone remodeling. The biological rationale for a gut–bone axis is well supported, but the clinical relevance of microbiome-targeted interventions remains uncertain. In this narrative review, w...
Sorina Ispas, V. Maggio, A. Wali et al.· Nutrients· 0 citations
Breast cancer remains the most frequently diagnosed malignancy among women worldwide, and increasing evidence indicates that the gut microbiome plays a significant role in tumor initiation, progression, and therapeutic response. Microbial dysbiosis and altered metabolite production have been associated with systemic in...
A. Wali, S. Talath, I. Rangraze et al.· BioMed Research Internationa...· 0 citations
Within nab-paclitaxel-containing neoadjuvant backbones, checkpoint-inhibitor addition was associated with higher pCR in randomized comparative evidence, and should not be interpreted as a cross-regimen comparison because of clinical and methodological heterogeneity.
R. A. Salama, M. El-Tanani, S. A. Rabbani et al.· Journal of Clinical Medicine· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
